Glivec
Sponsors
Hadassah Medical Organization, Gustave Roussy, Cancer Campus, Grand Paris, Institut Bergonié, Central European Cooperative Oncology Group, PETHEMA Foundation
Conditions
AMLAcute Lymphoblastic LeukemiaAdvanced or Metastatic Cholangiocellular Carcinoma and Bile DuctCancerChronic Myeloid LeukaemiaChronic Myeloid LeukemiaCromosome Philadelphia PositiveGastrointestinal Stromal Tumor
Phase 1
Phase 2
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
WithdrawnNCT00159016
Start: 2002-08-31End: 2005-09-30Target: 100Updated: 2011-04-28
Glivec Phase II Pediatric Study
TerminatedNCT00180830
Start: 2003-12-31Target: 36Updated: 2006-09-11
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
TerminatedNCT00210119
Start: 2006-07-12End: 2009-03-31Updated: 2021-11-08
Glivec in Ph Positive Lymphoblastic Leukemia
CompletedNCT00388895
Start: 2002-06-30End: 2007-10-31Target: 35Updated: 2008-11-19
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
CompletedNCT00744081
Start: 2004-07-31End: 2010-12-31Target: 130Updated: 2023-03-10
Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct
CompletedNCT01153750
Start: 2007-04-30End: 2010-03-31Updated: 2010-06-30
Phase 3
Phase 4
Unknown Phase
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
NCT01613053
Updated: 2015-04-24
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
RecruitingNCT05282108
Start: 2022-07-20End: 2026-11-30Target: 240Updated: 2025-03-26